[go: up one dir, main page]

IN2013MU03121A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03121A
IN2013MU03121A IN3121MU2013A IN2013MU03121A IN 2013MU03121 A IN2013MU03121 A IN 2013MU03121A IN 3121MU2013 A IN3121MU2013 A IN 3121MU2013A IN 2013MU03121 A IN2013MU03121 A IN 2013MU03121A
Authority
IN
India
Prior art keywords
relates
amorphous vortioxetine
amorphous
vortioxetine
salts
Prior art date
Application number
Inventor
Shri Prakash Dhar Dwivedi
Brij Khera
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to US14/916,075 priority Critical patent/US10414741B2/en
Priority to IN3121MU2013 priority patent/IN2013MU03121A/en
Priority to PCT/IN2014/000633 priority patent/WO2015044963A1/en
Publication of IN2013MU03121A publication Critical patent/IN2013MU03121A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ABSTRACT “AN AMORPHOUS VORTIOXETINE AND SALTS THEREOF” The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates topharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).
IN3121MU2013 2013-09-30 2014-09-30 IN2013MU03121A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/916,075 US10414741B2 (en) 2013-09-30 2014-09-30 Amorphous vortioxetine and salts thereof
IN3121MU2013 IN2013MU03121A (en) 2013-09-30 2014-09-30
PCT/IN2014/000633 WO2015044963A1 (en) 2013-09-30 2014-09-30 An amorphous vortioxetine and salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3121MU2013 IN2013MU03121A (en) 2013-09-30 2014-09-30

Publications (1)

Publication Number Publication Date
IN2013MU03121A true IN2013MU03121A (en) 2015-07-17

Family

ID=52117938

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3121MU2013 IN2013MU03121A (en) 2013-09-30 2014-09-30

Country Status (3)

Country Link
US (1) US10414741B2 (en)
IN (1) IN2013MU03121A (en)
WO (1) WO2015044963A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ201531A3 (en) * 2015-01-21 2016-08-03 Zentiva, K.S. Polymer-stabilized amorphous forms of vortioxetine
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2017041680A1 (en) * 2015-09-07 2017-03-16 常州方楠医药技术有限公司 Pharmaceutical composition of vortioxetine or salt thereof, and preparation method therefor
CN106491604A (en) * 2015-09-07 2017-03-15 常州方楠医药技术有限公司 A kind of unformed fertile compositionss for Xi Ting or its salt and pharmaceutic adjuvant and preparation method thereof
CZ2015633A3 (en) * 2015-09-16 2017-03-29 Zentiva, K.S. The amorphous form of vortioxetine hydrobromide stabilized with cyclodextrin
CN106556663B (en) * 2015-09-30 2018-05-29 成都弘达药业有限公司 A kind of detection method of 1- [2- (2,4- dimethylphenylsulfanyls) phenyl] piperazines or its salt
WO2017125504A1 (en) * 2016-01-20 2017-07-27 Amneal Pharmaceuticals Company Gmbh Polymorphic forms of vortioxetine hydrobromide tert-butanolate
WO2018042168A1 (en) * 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106518807A (en) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 Preparation method of lactic acid vortioxetine crystal form
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3582759A4 (en) * 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF PRE-ORDIOXETINE HYDROBROMIDE
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN114796222B (en) * 2019-09-04 2024-03-29 普济生物科技（台州）有限公司 Coated granules, solid dispersions and formulations containing vortioxetine hydrobromide for oral taste masking
TR202001040A2 (en) * 2020-01-23 2021-07-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Crystalline form c of vortioxetine hydrobromide
CN112830906B (en) * 2020-12-31 2022-05-13 微研优仿医药科技(江苏)有限公司 Preparation method of vortioxetine hydrobromide alpha crystal form
CN113143886A (en) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 Preparation method of vortioxetine hydrobromide pellet sustained-release preparation
CN115160258B (en) * 2022-06-24 2023-11-17 辰欣药业股份有限公司 Preparation method of vortioxetine hydrobromide gamma crystal form
WO2025132869A1 (en) * 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
JP2025109162A (en) * 2024-01-11 2025-07-24 Cbc株式会社 Amorphous solid form of vortioxetine hydrobromide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119521A (en) * 1871-10-03 Improvement in machines for rolling tapering forms
UA81749C2 (en) 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
ZA200810017B (en) 2006-06-16 2010-04-28 Lundbeck & Co As H 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
BR112014016322B8 (en) 2012-01-03 2020-12-01 H Lundbeck As process for the preparation of 1- [2- (2,4-dimethyl-phenylsulfanyl) -phenyl] -piperazine
US9499504B2 (en) * 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
WO2014177491A1 (en) * 2013-04-29 2014-11-06 Lek Pharmaceuticals D.D. New solid form of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide
WO2016062860A1 (en) * 2014-10-24 2016-04-28 H E X A L Aktiengesellschaft Amorphous vortioxetine hydrobromide

Also Published As

Publication number Publication date
US20160214949A1 (en) 2016-07-28
WO2015044963A9 (en) 2015-05-07
US10414741B2 (en) 2019-09-17
WO2015044963A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
IN2013MU03121A (en)
CY1122648T1 (en) PROCESS FOR THE PREPARATION OF COMPOSITIONS CONTAINING HYALURONIC ACID AND MEPIVACAINE HYDROCHLORIDE
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
NZ710270A (en) Pyridone amides as modulators of sodium channels
MX368833B (en) Quinoline and quinazoline amides as modulators of sodium channels.
MX2015016983A (en) Nuclear transport modulators and uses thereof.
PH12016500431A1 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
UA117261C2 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
IN2014DN09434A (en)
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
IN2014DN06169A (en)
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2016005760A (en) Gsk-3 inhibitors.
UA115357C2 (en) Pyridin-4-yl derivatives
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
MX360048B (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoq uinoline-3-carbonyl]-amino}-acetic acid.
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
UA115583C2 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2016008150A (en) Berberine formulations and uses thereof.
MX394633B (en) Nmda antagonist prodrugs
IN2013MU01111A (en)
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
MX2015015746A (en) Process for preparation of arformoterol of salt thereof.
IN2013MU03565A (en)
IN2013MU03428A (en)